For localized EGFR-mutant NSCLC, despite the fact that osimertinib has been well established in the adjuvant setting, neoadjuvant EGFR-TKIs did not yield a satisfactory pathological response compared to immunotherapy, with an MPR ranging from only 10%–15%.12 Here, EGFR is linked to non-small cell lung carcinoma.